Trials / Completed
CompletedNCT00150072
Efficacy and Safety of Imatinib in Chordoma
Phase II Study of Imatinib Mesylate in Chordoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical and pathological response. Aim of the study will be to explore treatment's activity, but also the potential impact of tumor response, the feasibility and outcome of subsequent surgery and radiotherapy. In addition, patterns of tumour response need to be investigated as well, given the peculiar patterns of response shown with molecular-targeted therapy in solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | imatinib |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2005-09-08
- Last updated
- 2017-02-23
Locations
12 sites across 2 countries: Italy, Switzerland
Source: ClinicalTrials.gov record NCT00150072. Inclusion in this directory is not an endorsement.